Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.